Heron Therapeutics Statistics
Total Valuation
HRTX has a market cap or net worth of $280.29 million. The enterprise value is $398.77 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, before market open.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HRTX has 152.33 million shares outstanding. The number of shares has increased by 10.36% in one year.
| Current Share Class | 152.33M |
| Shares Outstanding | 152.33M |
| Shares Change (YoY) | +10.36% |
| Shares Change (QoQ) | +0.21% |
| Owned by Insiders (%) | 0.76% |
| Owned by Institutions (%) | 52.78% |
| Float | 115.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.94 |
| Forward PS | 1.72 |
| PB Ratio | -8.33 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.29
| Current Ratio | 2.29 |
| Quick Ratio | 1.51 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.91 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -3.16% |
| Return on Invested Capital (ROIC) | -4.97% |
| Return on Capital Employed (ROCE) | -8.14% |
| Revenue Per Employee | $1.18M |
| Profits Per Employee | -$111,311 |
| Employee Count | 122 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 1.16 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.37% in the last 52 weeks. The beta is 1.40, so HRTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -37.37% |
| 50-Day Moving Average | 2.07 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 39.27 |
| Average Volume (20 Days) | 1,149,898 |
Short Selling Information
The latest short interest is 32.52 million, so 21.35% of the outstanding shares have been sold short.
| Short Interest | 32.52M |
| Short Previous Month | 32.07M |
| Short % of Shares Out | 21.35% |
| Short % of Float | 28.04% |
| Short Ratio (days to cover) | 16.42 |
Income Statement
In the last 12 months, HRTX had revenue of $144.29 million and -$13.58 million in losses. Loss per share was -$0.09.
| Revenue | 144.29M |
| Gross Profit | 88.95M |
| Operating Income | -11.53M |
| Pretax Income | -48.13M |
| Net Income | -13.58M |
| EBITDA | -9.04M |
| EBIT | -11.53M |
| Loss Per Share | -$0.09 |
Full Income StatementBalance Sheet
The company has $59.28 million in cash and $177.76 million in debt, giving a net cash position of -$118.48 million or -$0.78 per share.
| Cash & Cash Equivalents | 59.28M |
| Total Debt | 177.76M |
| Net Cash | -118.48M |
| Net Cash Per Share | -$0.78 |
| Equity (Book Value) | -33.65M |
| Book Value Per Share | -0.22 |
| Working Capital | 117.56M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.53 million and capital expenditures -$1.71 million, giving a free cash flow of -$24.24 million.
| Operating Cash Flow | -22.53M |
| Capital Expenditures | -1.71M |
| Free Cash Flow | -24.24M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
Gross margin is 61.65%, with operating and profit margins of -7.99% and -9.41%.
| Gross Margin | 61.65% |
| Operating Margin | -7.99% |
| Pretax Margin | -9.41% |
| Profit Margin | -9.41% |
| EBITDA Margin | -6.26% |
| EBIT Margin | -7.99% |
| FCF Margin | n/a |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.36% |
| Shareholder Yield | n/a |
| Earnings Yield | -4.85% |
| FCF Yield | -8.65% |
Analyst Forecast
The average price target for HRTX is $5.67, which is 208.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.67 |
| Price Target Difference | 208.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 13.16% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on January 13, 2014. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
HRTX has an Altman Z-Score of -9.65 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.65 |
| Piotroski F-Score | 2 |